All In Biotech

Drug Trial Radar · NCT00459173

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

Comparison of the Efficacy and Safety of 2 Oral Doses of Rimonabant, 5 mg/Day or 20 mg/Day, Versus Placebo, as an Aid to Maintenance of Smoking Cessation (1-Year Treatment, 1-Year Follow-up)

Last checked: Nov 20, 2026Latest source record: Apr 7, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 4,850 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,850

Actual

Start

Nov 2002

Primary completion

Sep 2005

Study completion Sep 2005

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 11, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary study objective is to evaluate the efficacy of 2 dose levels of rimonabant (5 mg and 20 mg) for the maintenance of abstinence from smoking. Secondary objectives are to evaluate the effect of rimonabant on craving and weight, the clinical and biological safety of 2 doses of rimonabant rimonabant during a 12-month treatment period and to evaluate the pharmacokinetics of the drug.

Conditions

  • Maintenance of Smoking Cessation

Interventions

  • rimonabant (SR141716)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to smoking relapse from the point of re-randomization (Week 10) through Week 32
  2. Smoking relapse defined as: any 7 or more consecutive days of smoking (even a puff) or any 2 consecutive days of smoking 5 or more cigarettes per day

Locations

3 sites in 3 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis

    Bridgewater, New Jersey

  • Sanofi-Aventis

    Cove, New South Wales, Australia

  • Sanofi-Aventis

    Laval, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.